The Analgesic Efficacy of Protocol for Primary Total Knee Arthroplasty (TKA)

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a perspective, randomized, blinded study with a parallel design and an allocation ratio of 1 to 1 for the treatment groups to assess the analgesic efficacy of adding the iPACK (injection between the popliteal artery and the capsule of the knee) in addition to the adductor canal block (ACB) for Total Knee Arthoplasty patients (TKA).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Treatments: Anesthetics; Anesthetics, Local

Criteria

Inclusion Criteria:

• Patients scheduled for total knee arthroplasty

• American Society Anesthesiologists (ASA) physical status I- III.

• Mentally competent and able to give consent for enrollment in the study.

Exclusion Criteria:

• Patient refusal,

• allergy to local anesthetics, systemic opioids (fentanyl, morphine, hydromorphone, and any of the drugs included in the multimodal perioperative pain protocol (MP3).

• Revision surgery will be excluded.

• Impaired kidney functions

• patient with coagulopathy will be also excluded.

• Chronic pain syndromes and patients with chronic opioid use in excess of a daily morphine equivalent dose (MED) of 40mg or greater for the past 3 months prior to the surgery.

• BMI of 45 or more